Predictive factors for composite reversion after HBsAg seroclearance
| Univariate analysis | Multivariable analysis* | |||||
|---|---|---|---|---|---|---|
| Variables | HR | 95% CI | p Value | HR | 95% CI | p Value |
| Age | 1.04 | 1.00 to 1.08 | 0.13 | 1.04 | 0.99 to 1.09 | 0.14 |
| Gender (male) | 1.71 | 0.49 to 5.90 | 0.40 | |||
| HBeAg positivity | 1.73 | 0.65 to 4.61 | 0.28 | |||
| HBV DNA level (log10 IU/mL) | 1.14 | 0.87 to 1.50 | 0.33 | |||
| ALT ≥ 40 IU/L | 1.56 | 0.21 to 11.7 | 0.67 | |||
| Cirrhosis | 1.68 | 0.63 to 4.47 | 0.30 | |||
| Selection for drug-resistance HBV mutants† | 0.73 | 0.24 to 2.22 | 0.58 | |||
| Duration of treatment (months) | 0.99 | 0.97 to 1.01 | 0.18 | 0.99 | 0.97 to 1.01 | 0.23 |
| Anti-HBs seroconversion during follow-up | 0.18 | 0.02 to 0.80 | 0.02 | 0.21 | 0.02 to 0.89 | 0.03 |
Composite reversion was defined as virological reversion and/or HBsAg reversion.
Predictive factors are at the initiation of antiviral therapy unless specified.
Total number of patients, 110; event (composite reversion) number, 18.
Extended Cox proportional hazards model for time-dependent covariate (anti-HBs seroconversion).
*Multivariable analysis including variables with p<0.25 at univariate analysis.
†During antiviral therapy before HBsAg seroclearance.
ALT, alanine aminotransferase.